Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Young, G.P. et al.

A randomized comparison of atropine and metaproterenol inhalational therapies for refractory status asthmaticus.

STUDY OBJECTIVE: To compare the forced expiratory volume in one second (FEV1) response to inhaled anticholinergic with the response to beta-adrenergic solutions in adults with refractory status asthmaticus. DESIGN: After the decision was made to hospitalize, 40 patients were prospectively randomized in a double-blind trial to receive either atropine sulfate or metaproterenol by nebulizer. SETTING: A county teaching hospital emergency department. TYPE OF PARTICIPANTS: Adults requiring hospitalization for refractory status asthmaticus. INTERVENTIONS: Standard therapies for acute bronchospasm, followed by either 1.5 mg atropine or 15 mg metaproterenol by nebulizer. MEASUREMENTS AND MAIN RESULTS: The two groups were similar on entry into the study, including mean FEV1 measurements (0.70 L atropine/0.60 L metaproterenol, P greater than .05). Compared with baseline, The FEV1 improvement for the metaproterenol group was statistically significant (+ 0.18 L, P = .05; + 31%, P less than .05), whereas the improvement with atropine did not reach significance (+0.09 L or +10%, P greater than .05). Comparing the two groups, statistically significant differences favoring metaproterenol were found in the percent improvement in the FEV1 (+10% atropine/+31% metaproterenol, P less than .05) and in the percentage of patients experiencing at least a 15% decrease in their FEV1 below baseline (35% atropine/10% metaproterenol, P less than .05). No patient suffered adverse side effects. CONCLUSION: For the majority of adults with refractory status asthmaticus, an additional beta-adrenergic inhalation treatment results in greater FEV1 improvement than that resulting from the addition of an atropine inhalation.[1]

References

A randomized comparison of atropine and metaproterenol inhalational therapies for refractory status asthmaticus. Young, G.P., Freitas, P. Annals of emergency medicine. (1991) [Pubmed]

Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.